About Current BioData
Current BioData, established by the founders of Swiss-Prot and the Investigational Drugs database (IDdb), combines their unrivalled knowledge and experience of biological data collection, integration and evaluation with expertise drawn from a global network of independent scientific opinion leaders
more
Focus on The Targeted Proteins database
The Targeted Proteins database (TPdb) is a daily updated monitoring service, developed for use by companies involved in the R&D of the human proteosome as a source of potential drug targets.
The challenge for these companies is to manage the recent explosion in genomic and proteomic data and the rapidly increasing knowledge about the proteins, enzymes and substrates involved. The TPdb has been developed to gather, filter and critically evaluate this mass of information so that it can be used in a way to enhance, rather than hinder, R&D efficiency.
Constructed around sets of proteins of crucial interest to drug researchers, the TPdb provides web access to consolidated, relevant information gathered from disparate research communities and updated on a daily basis.
Over and above this process, the information is further analysed and evaluated by international networks of relevant protein experts, set up as Virtual Academies, to highlight the more interesting aspects and add value by commenting on it’s possible impact on drug R&D.
TPdb can help you to find out....
What are the basic established facts about human proteins in homeostasis and disease?
Which proteins in a given system/pathway have been implicated in which diseases/disorders?
What are the most recent findings on a given protein and do they potentially impact drug research?
How well validated is a given protein as a potential drug target?
What evidence is there in the literature to support its validation status?
What do leading experts in the field think about this evidence?
Which academic research institutes or commercial organizations are working in a given protein field and what are they publishing and patenting?
What drugs are already known to interact with the protein, are they approved or still under development?
For a short demonstration of the database, go to www.tpdb.info
News from Current BioData
- New TPdb Kinome Module launched
- Editorial coverage of meetings - new TPdb Meeting Reports
- Current BioData expansion welcomed by Government
- New Neurodegeneration module under development
Virtual Academies
The following "Virtual Academies", made up of internationally renowned scientists, have been established to provide opinions and analysis about new research on protein targets for drug development, with other Virtual Academies currently in development:
The UPS Virtual Academy is headed by Prof. John Mayer. |
The LS Virtual Academy is headed by Prof. Matthias Wymann. |
The EGFRs Virtual Academy is headed by Prof. Nancy Hynes. |
The ER Virtual Academy is headed by Prof. Steve Baylin. |
The Kinome Virtual Academy is headed by Prof.Tony Hunter |